At the BIO International Convention, arguably the largest and most important biopharma partnering event of the year with over 16,000 participants, it's all about getting the deal done. While the industry will very likely not see the extremely high level of licensing and M&A activity it did back in 2015, the year is shaping up to reach a respectable level closer to historical norms, according to Sachin Purwar, Senior Engagement Manager in the Commercial Strategy & Planning practice of inVentiv Health Consulting and one of the authors of the 2017 Dealmakers' Intentions Study -- the ninth in a series and a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries.
What are buyers interested in this year, and what do sellers have to offer? Where is there a buyers' market, and where a sellers' market? What are the hot therapeutic areas and technologies to watch? What is the discount rate spread, and what does that mean for getting deals done? Why is the deal success rate so low -- and why is this good news?
Host Jeff Stewart sits down with Sachin to answer these questions -- and discuss the year ahead for dealmaking in the biopharma industry.
The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.
The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you.
inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.
The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts.
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.
At the BIO International Convention, arguably the largest and most important biopharma partnering event of the year with over 16,000 participants, it's all about getting the deal done. While the industry will very likely not see the extremely high level of licensing and M&A activity it did back in 2015, the year is shaping up to reach a respectable level closer to historical norms, according to Sachin Purwar, Senior Engagement Manager in the Commercial Strategy & Planning practice of inVentiv Health Consulting and one of the authors of the 2017 Dealmakers' Intentions Study -- the ninth in a series and a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries.
What are buyers interested in this year, and what do sellers have to offer? Where is there a buyers' market, and where a sellers' market? What are the hot therapeutic areas and technologies to watch? What is the discount rate spread, and what does that mean for getting deals done? Why is the deal success rate so low -- and why is this good news?
Host Jeff Stewart sits down with Sachin to answer these questions -- and discuss the year ahead for dealmaking in the biopharma industry.
The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.
The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you.
inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.
The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts.
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.
Like what you’re hearing? Be sure to rate and review us!
We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.